Cargando…
Mavrilimumab for severe COVID-19
Autores principales: | Pourhoseingholi, Mohamad Amin, Shojaee, Sajad, Ashtari, Sara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834396/ https://www.ncbi.nlm.nih.gov/pubmed/33521662 http://dx.doi.org/10.1016/S2665-9913(20)30307-6 |
Ejemplares similares
-
Mavrilimumab for severe COVID-19
por: Khan, Adil Rashid, et al.
Publicado: (2020) -
Mavrilimumab for severe COVID-19 – Authors' reply
por: De Luca, Giacomo, et al.
Publicado: (2020) -
Three potential challenges in studying COVID-19 pandemic data: Chinese statistics, social media, and preprint servers
por: Pourhoseingholi, Mohamad Amin, et al.
Publicado: (2020) -
Predicting the mortality due to Covid-19 by the next month for Italy, Iran and South Korea; a simulation study
por: Shojaee, Sajad, et al.
Publicado: (2020) -
A cluster analysis of epidemiological and clinical factors associated with the accumulation process of the burden of COVID-19 in European countries
por: Shojaee, Sajad, et al.
Publicado: (2021)